Plaxedes Dambudzo Matabah, NP

Plaxedes Matabah practices at Mercy Medical Group, A Service Of Dignity Health Medical Foundation in Sacramento, California.

Plaxedes Matabah's NPI, 1174269468, was assigned on May 9, 2022. Plaxedes Matabah graduated from University of California, Davis School of Medicine in 2022. Plaxedes Matabah holds California license 95021746.

Plaxedes Matabah's primary practice is Mercy Medical Group, A Service of Dignity Health Medical Foundation, at 3000 Q St Fl 1 Fl 1, Sacramento, CA 95816-7058. The practice phone is (916) 560-0319.

Plaxedes Matabah's primary practice is Mercy Medical Group, A Service Of Dignity Health Medical Foundation in Sacramento, California. The medical group on file is Mercy Medical Group.

Dmand AI tracks the electronic health record (EHR) system at each site where Plaxedes Matabah practices. Vendor and product names are available with a free account.

Family is Plaxedes Matabah's primary specialty in the NPI Registry, under taxonomy code 363LF0000X. Plaxedes Matabah is licensed in California.

Dmand AI lists alcohol use disorders, alzheimer's disease, anxiety, arthritis, bipolar disorder, chronic diabetes, chronic kidney disease and chronic obstructive pulmonary disease (COPD) among the conditions Plaxedes Matabah treats.

CMS data shows 420 Medicare services from Plaxedes Matabah across 5 procedure codes in 2024, for 69 Medicare patients. Medicare paid $38,380 for them. Every service was in an office.

CMS counts 69 Medicare patients who saw Plaxedes Matabah in 2024. The largest group is 85 and over, with 34 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 42% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Plaxedes Matabah's median patient age at 85, with 50% women.

In 2024, Plaxedes Matabah wrote 1,141 Medicare Part D claims for 90 patients. 91% of them were for generic drugs. CMS names the drug for 842 of them, across 35 drugs with 11 or more claims each, at $32,052 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Plaxedes Matabah for performance year 2024, reported through an alternative payment model (APM). Plaxedes Matabah accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Plaxedes Matabah as offering telehealth.

Plaxedes Matabah graduated from University of California, Davis School of Medicine in 2022.